Tarsus Pharmaceuticals, Inc. Common Stock (TARS) — Analysis Summary
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) has a market cap of $2.74B with year-over-year revenue growth of +948.6%. Net margin stands at -63.2%. The stock trades at a P/E ratio of -23.7.
Key Takeaways
- Revenue changed +948.6% year-over-year
- Net margin of -63.2%
- P/E ratio of -23.7
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, TARS posted revenue growth of +948.6% and trades at a P/E of -23.7.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.